Trial Outcomes & Findings for PortionSize Study 2 Free-Living Evaluation (NCT NCT05166226)

NCT ID: NCT05166226

Last Updated: 2025-12-15

Results Overview

The primary analyses assessing equivalence between PortionSize™ and the criterion measure (and MyFitnessPal and the criterion measures) will rely on equivalence testing using the Two One-side T-test (TOST) method. The null hypothesis of an equivalence tests is that the means are nonequivalent, i.e., the confidence interval of the mean of the test condition exceeds the pre-specified error bound. The alternative hypothesis is that the means are equivalent, and the mean difference between the experimental method and gold standard is hypothesized to be zero. Differences in error from PortionSize™ compared to error from MyFitnessPal will be assessed using dependent samples t-tests, with error calculated as the difference between each experimental method and the criterion variable (e.g., energy intake values from PortionSize™ minus energy intake values from weighed foods). These procedures will also produce results indicating if the error from each method differs from zero.

Recruitment status

ACTIVE_NOT_RECRUITING

Target enrollment

45 participants

Primary outcome timeframe

Mean daily energy intake averaged across 3 day free-living period of each PortionSize app and MyFitnessPal app intervention.

Results posted on

2025-12-15

Participant Flow

Participant milestones

Participant milestones
Measure
PortionSize Followed by MyFitnessPal
This was a within-subjects, randomized, counterbalanced crossover design. Each participant completed two testing periods: Period 1 and Period 2. Participants were randomly assigned to one of two sequences: (1) PortionSize followed by MyFitnessPal, or (2) MyFitnessPal followed by PortionSize. PortionSize followed by MyFitnessPal group used the PortionSize app to estimate dietary intake during the first study period and switched to MyFitnessPal for the second period.
MyFitnessPal Followed by PortionSize
This was a within-subjects, randomized, counterbalanced crossover design. Each participant completed two testing periods: Period 1 and Period 2. Participants were randomly assigned to one of two sequences: (1) PortionSize followed by MyFitnessPal, or (2) MyFitnessPal followed by PortionSize. MyFitnessPal followed by PortionSize group used the MyFitnessPal app to estimate dietary intake during the first study period and switched to PortionSize for the second period.
Overall Study
STARTED
23
22
Overall Study
COMPLETED
23
21
Overall Study
NOT COMPLETED
0
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

PortionSize Study 2 Free-Living Evaluation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Participants
n=44 Participants
All 44 participants that completed the study
Age, Continuous
44.0 years
STANDARD_DEVIATION 10.8 • n=6009 Participants
Sex: Female, Male
Female
24 Participants
n=6009 Participants
Sex: Female, Male
Male
20 Participants
n=6009 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=6009 Participants
Race (NIH/OMB)
Asian
2 Participants
n=6009 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=6009 Participants
Race (NIH/OMB)
Black or African American
7 Participants
n=6009 Participants
Race (NIH/OMB)
White
35 Participants
n=6009 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=6009 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=6009 Participants
Region of Enrollment
United States
44 participants
n=6009 Participants
BMI
28.6 kilograms per square meter (kg/m²)
STANDARD_DEVIATION 6.7 • n=6009 Participants

PRIMARY outcome

Timeframe: Mean daily energy intake averaged across 3 day free-living period of each PortionSize app and MyFitnessPal app intervention.

Population: All participants completed two study periods using both the PortionSize and MyFitnessPal apps. Outcome measures are summarized by intervention (PortionSize vs. MyFitnessPal), pooling data across all participants regardless of the order in which apps were used.

The primary analyses assessing equivalence between PortionSize™ and the criterion measure (and MyFitnessPal and the criterion measures) will rely on equivalence testing using the Two One-side T-test (TOST) method. The null hypothesis of an equivalence tests is that the means are nonequivalent, i.e., the confidence interval of the mean of the test condition exceeds the pre-specified error bound. The alternative hypothesis is that the means are equivalent, and the mean difference between the experimental method and gold standard is hypothesized to be zero. Differences in error from PortionSize™ compared to error from MyFitnessPal will be assessed using dependent samples t-tests, with error calculated as the difference between each experimental method and the criterion variable (e.g., energy intake values from PortionSize™ minus energy intake values from weighed foods). These procedures will also produce results indicating if the error from each method differs from zero.

Outcome measures

Outcome measures
Measure
PortionSize
n=44 Participants
This was a within-subjects, randomized, counterbalanced crossover design. Each participant completed two testing periods: Period 1 and Period 2. Participants were randomly assigned to one of two sequences of interventions: (1) PortionSize followed by MyFitnessPal, or (2) MyFitnessPal followed by PortionSize.
MyFitnessPal
n=44 Participants
This was a within-subjects, randomized, counterbalanced crossover design. Each participant completed two testing periods: Period 1 and Period 2. Participants were randomly assigned to one of two sequences: (1) PortionSize followed by MyFitnessPal, or (2) MyFitnessPal followed by PortionSize.
Energy (Kilocalorie or kcal) Intake
2128.8 kcal/day
Standard Deviation 762.1
2120.0 kcal/day
Standard Deviation 650.1

Adverse Events

PortionSize

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

MyFitnessPal

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Corby Martin

Pennington Biomedical Research Center

Phone: +1 (225) 763-2585

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place